TELA Bio, Inc. TELA
- Market cap
- $57.3M
- P/E
- 0.0×
Follow TELA
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | 10.78 | 5.25 | 11.03 | 5.15 | 4.24 | 2.30 | 0.87 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| — | — | — | 15.05 | 23.55 | 18.00 | 13.70 | 13.18 | 7.84 | 3.10 |
High Price
|
|||
| — | — | 86 | 89 | 108 | 123 | 173 | 166 | 209 | 150 |
Employees
|
|||
| — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
Revenue/Emp
|
|||
| — | 4 | 8 | 15 | 18 | 29 | 41 | 58 | 69 | 80 |
Revenue
|
|||
| — | 59.65% | 45.04% | 62.00% | 63.35% | 64.88% | 67.24% | 69.27% | 67.63% | 68.17% |
Gross Margin
|
|||
| — | (21) | (21) | (22) | (29) | (33) | (44) | (47) | (38) | (39) |
EBT
|
|||
| — | (502.57%) | (254.92%) | (145.18%) | (158.10%) | (112.94%) | (106.95%) | (79.83%) | (54.81%) | (48.09%) |
EBT Margin
|
|||
| — | (21) | (21) | (22) | (29) | (33) | (44) | (47) | (38) | (39) |
Net Income
|
|||
| — | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
Depreciation
|
|||
| — | 14.54 | 28.05 | 8.75 | 1.41 | 2.04 | 2.55 | 2.56 | 2.43 | 1.71 |
Revenue/Sh
|
|||
| — | (73.06) | (71.50) | (17.10) | (2.23) | (2.30) | (2.72) | (2.04) | (1.33) | (0.83) |
Earnings/Sh
|
|||
| — | (56.05) | (67.54) | (14.45) | (1.89) | (2.10) | (2.50) | (1.79) | (1.46) | (0.60) |
Cash Flow/Sh
|
|||
| — | (0.35) | (5.28) | (1.53) | (0.01) | (0.04) | (0.12) | (0.03) | (0.03) | (0.01) |
Capex/Sh
|
|||
| — | (56.40) | (72.82) | (15.98) | (1.90) | (2.15) | (2.62) | (1.81) | (1.49) | (0.61) |
Free CF/Sh
|
|||
| — | (370.45) | (467.32) | 17.53 | 3.79 | 1.39 | 0.88 | 0.83 | 1.00 | 0.13 |
Book Value/Sh
|
|||
| — | 0 | 0 | 2 | 13 | 14 | 16 | 23 | 29 | 47 |
Shares
|
|||
| — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
PE Ratio
|
|||
| — | 0.31 | 0.31 | 1.48 | 10.68 | 6.29 | 4.52 | 2.59 | 1.24 | 0.69 |
PS Ratio
|
|||
| — | 0.00 | 0.00 | 0.74 | 3.97 | 9.22 | 13.08 | 8.02 | 3.03 | 8.78 |
PB Ratio
|
|||
| — | 1.90 | 1.90 | (0.04) | 8.34 | 5.90 | 4.47 | 2.49 | 1.08 | 0.79 |
EV/Sales
|
|||
| — | (0.91) | (0.91) | 0.02 | (5.60) | (5.18) | (4.15) | (3.27) | (1.64) | (2.01) |
EV/FCF
|
|||
| — | (16) | (20) | (26) | (24) | (30) | (41) | (41) | (42) | (28) |
Op' Cash Flow
|
|||
| — | 0 | (2) | (3) | 0 | (1) | (2) | (1) | (1) | 0 |
Capex
|
|||
| — | (16) | (21) | (28) | (25) | (31) | (43) | (41) | (43) | (29) |
FCF
|
|||
| — | 8 | 14 | 58 | 77 | 48 | 50 | 55 | 62 | 58 |
Working Cap'
|
|||
| — | 5 | 30 | 30 | 31 | 31 | 40 | 41 | 41 | 56 |
Total Debt
|
|||
| — | (7) | 12 | (24) | (44) | (12) | (2) | (6) | (12) | 5 |
Net Debt
|
|||
| — | (108) | (138) | 31 | 49 | 20 | 14 | 19 | 28 | 6 |
Sh' Equity
|
|||
| — | (127.35%) | (139.92%) | (63.50%) | (37.30%) | (44.67%) | (67.94%) | (63.97%) | (45.97%) | (46.23%) |
ROA
|
|||
| — | 0.00% | 0.00% | (180.96%) | (289.37%) | (240.36%) | (194.38%) | (217.47%) | (126.08%) | (189.70%) |
ROIC
|
|||
| — | 22.13% | 24.32% | 56.52% | (72.00%) | (96.28%) | (257.51%) | (281.23%) | (159.87%) | (223.35%) |
ROE
|
|||
TELA Bio, Inc. peers in Medical Devices
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| OM Outset Medical, Inc. | $58.8M | 0.0× | Compare |
| RPID Rapid Micro Biosystems, Inc. | $55.7M | 0.0× | Compare |
| COCH Envoy Medical, Inc. | $55.4M | 0.0× | Compare |
| NNOX Nano-X Imaging Ltd. | $53.4M | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| MDAI Spectral AI, Inc. | $53.1M | 0.0× | Compare |
| XTNT Xtant Medical Holdings, Inc. | $52.9M | 0.0× | Compare |
| MYO Myomo, Inc. | $64.6M | 0.0× | Compare |
| CVRX CVRx, Inc. | $67.4M | 0.0× | Compare |
TELA Bio, Inc. (TELA) key facts
- TELA Bio, Inc. (TELA) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
- TELA Bio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $80.3 million, up 15.8% from fiscal 2024.
- As of September 25, 2026, TELA traded at $1.26, a market capitalization of $57.3 million.
- Return on equity was −223.4% and debt-to-equity -3.53.
TELA Bio, Inc. (TELA) Latest News
31 Aug
TELA Bio announces COO and CFO transition alongside strategic cost reduction initiative. Leadership changes paired with cost cuts may moderately shift operational efficiency and financial outlook.
19 Aug
TELA Bio presented Q2 2026 earnings results and business outlook during its earnings call. Quarterly earnings releases and guidance typically drive major shifts in valuation and investor sentiment.
11 Aug
TELA Bio, Inc. reported its financial results for the second quarter of 2025, highlighting significant revenue growth and advancements in product offerings. The company experienced an increase in sales driven by strong demand for its innovative surgical solutions. Management expressed optimism about future growth prospects and ongoing investments in research and development. The results reflect TELA's strategic focus on expanding its market presence and enhancing its product portfolio to meet evolving customer needs. Significant revenue growth and strategic advancements indicate a strong potential for altering the company's trajectory.
TELA Bio Inc navigated PRS headwinds in Q2 2026 while pursuing strategic initiatives to support operations and positioning. Q2 2026 earnings call highlights PRS headwinds alongside strategic efforts that point to moderate operational and market effects.
TELA Bio, Inc. reported a loss in Q2 that fell short of revenue estimates, indicating challenges in its financial performance. The company's results reflect ongoing difficulties in achieving expected growth and may raise concerns among investors about its future trajectory. The reported loss and revenue shortfall may moderately influence investor sentiment and financial performance.
10 Aug
TELA Bio, Inc. released its Q2 2026 earnings call summary covering financial results, operational updates and forward outlook. Quarterly earnings call delivers updated financials and guidance that can shift near-term investor sentiment and valuation.
TELA Bio reported a Q2 loss and missed revenue estimates. Q2 loss combined with revenue shortfall points to weaker financial results that may weigh on near-term stock sentiment.
TELA Bio reported its second quarter 2026 financial results. Quarterly earnings updates can shift near-term investor sentiment and valuation for the company.
4 Aug
TELA Bio appoints Heather Getz as Chief Executive Officer and Director. CEO appointment may shift strategy and sentiment without altering core trajectory.
15 May
Analysts cut TELA Bio, Inc. (NASDAQ:TELA) price target to US$2.25 following disappointing earnings release. Analyst price target reduction signals moderately negative impact on market sentiment and financial outlook.
13 May
TELA Bio, Inc. Q1 2026 earnings call summary covers quarterly financial results, operational updates, and forward guidance. Quarterly earnings disclosures reveal financial health and strategic outlook, significantly shaping investor sentiment and stock trajectory.
TELA Bio Inc reported strong European growth and strategic U.S. initiatives in Q1 2026 earnings call, highlighting robust performance and expansion plans. Strong European growth and strategic U.S. moves represent major positive developments poised to significantly enhance TELA's market position and trajectory.
12 May
TELA Bio, Inc. (TELA) reported first quarter 2026 financial results. Quarterly financial results directly impact stock performance, investor sentiment, and future projections.
TELA Bio, Inc. (TELA) reported a first-quarter net loss while beating revenue estimates. Q1 loss despite revenue beat reflects mixed financial results with moderate influence on financial performance and market sentiment.
30 Apr
TELA Bio appoints four highly experienced commercial leaders to its board to accelerate growth and drive path to profitability; reports preliminary first quarter 2026 revenues. Board refreshment with commercial experts targets growth acceleration and profitability alongside preliminary Q1 2026 revenues, marking a major strategic move.
25 Mar
TELA Bio, Inc. released Q4 2025 earnings call summary detailing financial results, operational updates, and forward guidance. Q4 earnings call summary highlights financial performance and strategic outlook significantly influencing stock trajectory and investor sentiment.
24 Mar
TELA Bio Inc. posted record revenue growth in Q4 2025 earnings call, driven by strategic initiatives amid expanding market presence. Record revenue growth and strategic moves signal major positive shifts in financials and competitive positioning.
TELA Bio (TELA) Q4 2025 earnings call transcript covers quarterly financial results, operational updates, strategic initiatives, and forward guidance. Q4 earnings call transcript delivers critical financial metrics, revenue growth, and outlook shaping investor expectations and stock trajectory.
TELA Bio, Inc. (TELA) reported fourth quarter and full year 2025 financial results. Full-year financial results reporting significantly influences investor sentiment, stock valuation, and future performance expectations.
TELA Bio, Inc. (TELA) reported a Q4 loss and revenue below analyst estimates. Q4 loss and revenue miss highlight weaker financial results, potentially affecting short-term market sentiment and performance.
14 Nov
TELA Bio, Inc. reported significant revenue growth in Q3 2025, driven by strategic expansions and product innovations. The company highlighted its commitment to enhancing its market presence and improving operational efficiencies. Key financial metrics showed positive trends, indicating a robust performance that positions TELA favorably for future growth. Strategic expansions and revenue growth are likely to significantly impact TELA's future performance and market positioning.
13 Nov
TELA Bio, Inc. reported its financial results for the third quarter of 2025, highlighting improvements in revenue and operational efficiency. The company also announced the refinancing and upsizing of its credit facility, which is expected to enhance its financial flexibility and support future growth initiatives. The refinancing and upsizing of the credit facility is a significant strategic move that could enhance financial stability and support growth.
TELA Bio, Inc. reported a loss in Q3 and fell short of revenue estimates, indicating challenges in its financial performance. The company continues to face hurdles in achieving its growth targets, which may raise concerns among investors regarding its future prospects. The missed revenue estimates and reported loss suggest moderate challenges that could affect financial performance and investor sentiment.
TELA Bio, Inc. has announced the pricing of a $13.0 million underwritten registered direct offering of common stock and pre-funded warrants. The offering is expected to close on or about October 30, 2023, subject to customary closing conditions. The proceeds from the offering will be used for general corporate purposes, including working capital and potential future acquisitions. The capital raised may support operational needs and growth initiatives, but the overall impact on the company's trajectory is expected to be limited.
3 Nov
TELA Bio, Inc. has appointed William Plovanic to its Board of Directors, enhancing its leadership team. Plovanic brings extensive experience in the medical device industry, having held various executive roles. His expertise is expected to contribute to TELA's strategic initiatives and growth in the regenerative medicine sector. The appointment of a seasoned executive may positively influence TELA's strategic direction and operational effectiveness.
9 Oct
Insider buying activity at TELA Bio, Inc. has been noted, with multiple executives purchasing shares of the company's stock. This trend is often seen as a positive indicator of confidence in the company's future performance and prospects. The increased insider ownership may signal a belief in the company's growth potential and stability, potentially influencing investor sentiment positively. Insider purchases can indicate confidence in the company's future, which may moderately influence market sentiment and performance.
12 Aug
TELA Bio, Inc. reported record revenue in Q2 2025, highlighting significant strategic growth initiatives. The company emphasized its commitment to innovation and expanding its market presence, which contributed to strong financial performance. Management provided insights into future plans and ongoing projects aimed at enhancing product offerings and operational efficiency. Record revenue and strategic growth initiatives are likely to significantly impact TELA's future performance and market positioning.
2 Jul
TELA Bio, Inc. (NASDAQ:TELA) is nearing breakeven, with analysts predicting a final loss in 2026 and positive profits of US$1.1m in 2027, requiring an average annual growth rate of 69%. The company's recent loss widened to US$43m, raising concerns about its financial trajectory. Additionally, TELA Bio has a debt-to-equity ratio exceeding 2x, indicating significant financial risk. A comprehensive analysis of TELA Bio's fundamentals is recommended for potential investors. The projected breakeven timeline and high growth rate expectations indicate a moderately noticeable influence on TELA's future performance.
7 Jun
Aroa Biosurgery Ltd reported strong earnings for FY25, surpassing revenue expectations and demonstrating significant growth in its product offerings. The company highlighted advancements in its technology and market penetration, which contributed to its positive financial performance. Analysts noted the potential for continued success as Aroa expands its reach in the biosurgery market, positioning itself favorably against competitors. Aroa's strong earnings and growth potential may moderately influence TELA's competitive positioning in the biosurgery market.
3 Jun
TELA Bio, Inc. has launched OviTex Inguinal Reinforced Tissue Matrix in Europe, designed for laparoscopic and robotic-assisted inguinal hernia repair. Following a successful U.S. launch in 2024 with over $1 million in sales, OviTex Inguinal offers surgeons tailored options with three- or four-layer configurations. The product is based on ovine tissue and has demonstrated clinical efficacy with a low recurrence rate in studies. TELA Bio aims to meet the growing demand for naturally derived surgical solutions in Europe, showcasing the product at the European Hernia Society Annual Congress in Paris. The European launch of OviTex Inguinal represents a significant strategic move that could enhance TELA's market position and financial performance.